Deals channel feed – Endpoints News

Deals channel feed

Further setting the stage for going public, Vivek Ramaswamy’s Roivant readies a deal to buy up a Vant’s stock — cheap

5 years ago

Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90% premium sealed the deal — along with $17.6M in ‘retention’ incentives

5 years ago

After three years of courtship (and turndowns), Merck pounced on the first glance of clinical data in $1.85B Pandion takeover

5 years ago

Amgen snaps up cancer drug player Five Prime, adding PhIII-ready FGFR2b drug in $2B M&A play

5 years ago

Thank you, next: Takeda hands Ovid $196M cash to rein back in Phase III-ready seizure drug, reviving battered stock

5 years ago

AbbVie tees up a biotech buyout after sizing up their Parkinson's drug spun out of Kevan Shokat's lab

5 years ago

A 'love story': WuXi AppTec wraps UK-based CRO into its cell and gene therapy unit

5 years ago

Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria

5 years ago

Angling Pfizer, AstraZeneca jumps into commercial PD-(L)1 fight in China

5 years ago

Merck KGaA earmarks $855M for Debiopharm's programmed cell death promoting drug in global licensing deal

5 years ago

Roche and Genentech researchers plot $53M discovery quest aimed at sparking a 'Holy moly' pivot in neuro R&D

5 years ago

Roivant parlays a $450M chunk of equity in biotech buyout, grabbing a computational group to drive discovery work

5 years ago

Merck takes a swing at the IL-2 puzzlebox with a $1.85B play for buzzy Pandion and its autoimmune hopefuls

5 years ago

In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sciences to focus on decentralized clinical work

5 years ago

Biotech upstart adds a failed Merck KGaA drug to the pipeline, mapping new combo approach to MAPK pathway

5 years ago

Beam turns its soaring valuation into new assets, buying out an under-the-radar spinout and their gene delivery tech

5 years ago

Charles River Laboratories snaps up Cognate for a cool $875M, looks to expand cell and gene therapy CDMO foothold

5 years ago

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

5 years ago

Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial

5 years ago

Novartis partners with the Gates Foundation on one of the Holy Grails in gene therapy: a simple, in vivo approach to curing sickle cell disease

5 years ago

Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies

5 years ago

Quotient, buoyed by Covid-19 work, buys Arcinova in effort to build end-to-end CDMO brand

5 years ago

Bristol Myers takes next big gamble on I/O frontier, pledging nearly $1.4B on Texas firm's tumor toxins

5 years ago

Novartis' Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes

5 years ago

First page Previous page 78 79 808182 83 84 Next page Last page